Tazidime

   
Google
 
Web NewDrugInformation.com

Tazidime


Drug - Tazidime
The trade name of the product as shown on the labeling.

Dosage - INJECTABLE; INJECTION
The product dosage form and route separated by a semi-colon.

Active Ingredient(s) - Ceftazidime
Multiple ingredients are in alphabetical order.

Strength - 1GM/VIAL
The potency of the active ingredient(s), Ceftazidime. May repeat for multiple part products.

Applicant - LILLY
The firm name holding legal responsibility for Tazidime. The firm name is condensed to a maximum twenty character unique string.

New Drug Application (NDA) Number - 062655
The FDA assigned number to Tazidime. Format is nnnnnn.

Product Number - 001
The FDA assigned number to identify Tazidime. Each strength is a separate product. May repeat for multiple part products. Format is nnn.

Therapeutic Equivalence (TE) Code -
The TE Code indicates the therapeutic equivalence rating of generic to innovator Rx products.

Approval Date - Nov 20, 1985
The date Tazidime was approved as stated in the FDA approval letter to the applicant. The format is Mmm dd, yyyy. Products approved prior to the January 1, 1982 contain the phrase: "Approved prior to Jan 1, 1982".

Reference Listed Drug (RLD) - No
The pioneer or innovator of Tazidime. The RLD identifies the product Abbreviated New Drug Applications (ANDA) use as a reference. Format is Yes or No.

Type - DISCN
The group or category of approved drugs Tazidime is in. Format is RX, OTC, DISCN.

Applicant Full Name - Eli Lilly And Co
The full name of the firm holding legal responsibility for the new application of Tazidime.

Tazidime